Meeting
2022 ASCO Genitourinary Cancers Symposium
Real-world analyses of major adverse cardiovascular event risk by drug class after initiation of androgen deprivation therapy.
Authors
E. David Crawford
University of California San Diego, Koman Family Outpatient Pavilion, San Diego, CA
E. David Crawford , Stuart Atkinson , Deborah Boldt-Houle , Lucio N. Gordan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 46)
DOI
10.1200/JCO.2022.40.6_suppl.046
Abstract #
46
Poster Bd #
B10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world combination therapy patterns in patients receiving leuprolide or relugolix for androgen deprivation therapy in 2021 (The REAL-ADT COMBO Study): Analysis from a US EMR database.
First Author: Rana R. McKay
Poster
2018 Genitourinary Cancers Symposium
Cardiovascular comorbidities in German prostate cancer patients under androgen deprivation therapy: Results from a retrospective analysis of patient data in urological outpatient centers.
First Author: Andreas Eisenhardt
Poster
2024 ASCO Genitourinary Cancers Symposium
Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): An initial analysis of patient treatment preferences and quality of life.
First Author: Sagar A. Patel
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan